Table 2.
Complications and adverse events in different therapy groups
| Complications | Conservative therapy (n=51) | TACE group (n=31) | Radiotherapy (n=10) | P-value |
|---|---|---|---|---|
| Nausea, vomiting, n (%) | 12 (24) | 18 (58) | 2 (20) | 0.003* |
| Fever, n (%) | 8 (16) | 11 (35) | 2 (20) | 0.130 |
| Pain, n (%) | 30 (60) | 22 (71) | 6 (60) | 0.547 |
| Alopecia, n (%) | 0 (0) | 1 (3) | 0 (0) | 0.446 |
| Liver function impairment, n (%) | 6 (12) | 4 (13) | 2 (20) | 0.736 |
| Bleeding of esophageal venous plexus, n (%) | 1 (2) | 0 (0) | 0 (0) | >0.999 |
| Gastrointestinal hemorrhage, n (%) | 0 (0) | 1 (1) | 0 (0) | 0.446 |
| Infection, n (%) | 4 (8) | 3 (10) | 1 (10) | >0.999 |
| Refractory ascites, n (%) | 1 (2) | 0 (0) | 0 (0) | >0.999 |
| Pulmonary complication, n (%) | 2 (4) | 2 (6) | 0 (0) | 0.769 |
| Bone marrow suppression, n (%) | 0 (0) | 1 (3) | 1 (10) | 0.085 |
| Clavien–Dindo complications, grade I/II/III/IV, n | 40/8/3 | 23/6/2 | 7/2/1 | 0.906 |
Notes:
*
P<0.05. Subgroup analysis depending on PVTT type.
Abbreviations: PVTT, portal vein tumor thrombus; TACE, transarterial chemoembolization.